DB:S46

Stock Analysis Report

Executive Summary

Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally.


Snowflake Analysis

Excellent balance sheet and fair value.

Share Price & News

How has Stemline Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: S46's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-0.5%

S46

11.3%

DE Biotechs

7.1%

DE Market


1 Year Return

-63.3%

S46

-5.1%

DE Biotechs

-17.5%

DE Market

Return vs Industry: S46 underperformed the German Biotechs industry which returned -5.1% over the past year.

Return vs Market: S46 underperformed the German Market which returned -17.5% over the past year.


Shareholder returns

S46IndustryMarket
7 Day-0.5%11.3%7.1%
30 Day-24.6%-8.0%-20.0%
90 Day-57.0%-22.7%-26.1%
1 Year-63.3%-63.3%-4.9%-5.1%-15.0%-17.5%
3 Year-49.1%-49.1%17.7%16.4%-18.8%-25.8%
5 Year-70.6%-70.6%-5.1%-7.5%-17.9%-29.2%

Price Volatility Vs. Market

How volatile is Stemline Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Stemline Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: S46 (€3.96) is trading below our estimate of fair value (€42.34)

Significantly Below Fair Value: S46 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: S46 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: S46 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate S46's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: S46 is good value based on its PB Ratio (1.3x) compared to the DE Biotechs industry average (3.6x).


Next Steps

Future Growth

How is Stemline Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

52.0%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: S46 is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: S46 is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: S46 is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: S46's revenue (32.4% per year) is forecast to grow faster than the German market (4.2% per year).

High Growth Revenue: S46's revenue (32.4% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: S46 is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Stemline Therapeutics performed over the past 5 years?

-24.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: S46 is currently unprofitable.

Growing Profit Margin: S46 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: S46 is unprofitable, and losses have increased over the past 5 years at a rate of -24.9% per year.

Accelerating Growth: Unable to compare S46's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: S46 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (8.7%).


Return on Equity

High ROE: S46 has a negative Return on Equity (-46.95%), as it is currently unprofitable.


Next Steps

Financial Health

How is Stemline Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: S46's short term assets ($185.2M) exceed its short term liabilities ($23.1M).

Long Term Liabilities: S46's short term assets ($185.2M) exceed its long term liabilities ($230.7K).


Debt to Equity History and Analysis

Debt Level: S46 is debt free.

Reducing Debt: S46 has not had any debt for past 5 years.


Balance Sheet

Inventory Level: S46 has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if S46's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: S46 has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if S46 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Stemline Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate S46's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate S46's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if S46's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if S46's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of S46's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

8.2yrs

Average management tenure


CEO

Ivan Bergstein (53yo)

16.58s

Tenure

US$9,441,653

Compensation

Dr. Ivan Bergstein, M.D., founded Stemline Therapeutics, Inc. in August 2003 and has been its Chairman, Chief Executive Officer and President. Dr. Bergstein served as the Medical Director of Keryx Biopharm ...


CEO Compensation Analysis

Compensation vs Market: Ivan's total compensation ($USD9.44M) is above average for companies of similar size in the German market ($USD765.33K).

Compensation vs Earnings: Ivan's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Ivan Bergstein
Founder16.58yrsUS$9.44m6.03% $11.3m
David Gionco
Senior VP of Finance & Chief Accounting Officer6.17yrsUS$2.14m0.67% $1.3m
Kenneth Hoberman
COO & Corporate Secretary8.17yrsUS$7.54m1.63% $3.1m
Robert Francomano
Chief Commercial Officerno datano data0.42% $785.5k
John Salvagno
Senior Vice President of Quality & Operationsno datano datano data

8.2yrs

Average Tenure

54yo

Average Age

Experienced Management: S46's management team is seasoned and experienced (8.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Ivan Bergstein
Founder16.58yrsUS$9.44m6.03% $11.3m
Kenneth Zuerblis
Independent Director8yrsUS$283.75k0.13% $238.6k
Alan Forman
Independent Director4.92yrsUS$290.73k0.19% $350.4k
Ron Bentsur
Independent Director11.17yrsUS$280.14k0.14% $259.7k
Hagop Kantarjian
Member of the Scientific Advisory Boardno datano datano data
Owen O'Connor
Member of the Scientific Advisory Boardno datano datano data
Patrick Wen
Member of the Scientific Advisory Boardno datano datano data
Darren Cline
Independent Director1.92yrsUS$382.31k0.075% $140.7k
David Reardon
Member of the Scientific Advisory Boardno datano datano data
Daniel Hume
Independent Director1.92yrsUS$382.97k0.075% $140.7k

6.5yrs

Average Tenure

53yo

Average Age

Experienced Board: S46's board of directors are considered experienced (6.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: S46 insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 48.3%.


Top Shareholders

Company Information

Stemline Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Stemline Therapeutics, Inc.
  • Ticker: S46
  • Exchange: DB
  • Founded: 2003
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$208.439m
  • Listing Market Cap: US$187.991m
  • Shares outstanding: 47.37m
  • Website: https://www.stemline.com

Number of Employees


Location

  • Stemline Therapeutics, Inc.
  • 750 Lexington Avenue
  • Eleventh Floor
  • New York
  • New York
  • 10022
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
STMLNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJan 2013
S46DB (Deutsche Boerse AG)YesCommon StockDEEURJan 2013

Biography

Stemline Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older. It also developing CD123 that is in Phase I/II clinical trials for the treatment of chronic myelomonocytic leukemia and myelofibrosis, as well as acute myeloid leukemia and multiple myeloma in combination with other therapies. In addition, the company is developing SL-801, a novel oral small molecule reversible inhibitor of nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that has completed Phase II clinical trials to treat brain cancer. Its preclinical pipeline products include SL-501, a CD123 targeted therapy; SL- 1001, an oral, selective small molecule RET kinase inhibitor targeting multiple oncology indications; and SL-901, a small molecule kinase inhibitor. Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/29 22:36
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.